2019 Speakers

Dr. Colin Reisner is Senior Vice President and Head of Late Stage RIA (Respiratory, Inflammation & Autoimmunity), BioPharmaceuticals R&D, AstraZeneca. He is an innovative leader with more than 20 years of international experience at top-tier companies, having previously workred at Boehringer Ingelheim, GSK and Novartis. Colin has extensive experience in both large and small companies,…

Pliant CEO Bernard Coulie, MD, PhD brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the…

Ted began his career with Merck & Co. in Clinical Pharmacology and Pulmonary-Immunology and eventually was responsible for other therapeutic areas within the company including Gastroenterology. Ted also worked at Covance, fostering an integrated approach to drug development, Vanderbilt School of Medicine in Molecular Toxicology and the Clinical and Translational Science Institute (CTSI) and joins…

Jeff Goldstein is a double lung transplant recipient (2003) and the Founding Member and President of the Lung Transplant Foundation (LTF). The LTF’s mission is to improve the lives of lung transplant recipients and is particularly interested in the development of therapies and technologies to treat BOS and rejection. Mr. Goldstein’s background is in business…

Tim Watkins is a Director of Clinical Research in Respiratory/Inflammation Therapeutics at Gilead Sciences. He has over a decade of experience in the biomedical and biopharmaceutical sectors, with clinical research spanning ARDS, trauma, sepsis, viral pneumonia and other aspects of inflammatory and respiratory diseases. At Gilead, Tim is responsible for the clinical development of drug…

Ms. Gonzalo is a Partner at Oberland Capital, a private investment firm with over $1.2 billion in capital commitments since inception, that is focused exclusively on investing in the global healthcare industry. Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners where she focused on venture capital and private equity investments…

Dennis Wahr, MD is the CEO of Nuvaira which is developing a unique minimally invasive bronchoscopic treatment for patients with chronic obstructive lung disease called Targeted Lung Denervation (TLD). Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its President and CEO until CR Bard acquired the company in December 2011.…